BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA

被引：0
|
作者：
Penayo, N. [1 ]
Peredo, S. [2 ]
Olivera, M. S. [1 ]
Weissberg, A. [1 ]
Tellechea, F. [1 ]
Saenz, V [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Tigre, Argentina
[2] F Hoffmann Roche Ltd, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN62
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [31] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [32] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [33] Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza
    Jafal, Mohamed
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 511 - 518
  • [34] Budget impact analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Aultman, R.
    Krzakowski, M.
    Pienkowski, T.
    Drosik, K.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2007, 10 (03) : A124 - A124
  • [35] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [36] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [37] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [38] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [39] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Burris, Howard A., III
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
  • [40] Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer
    Watanabe, Junichiro
    Ito, Yoshinori
    Saeki, Toshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Takao, Shintaro
    Nakagami, Kazuhiko
    Tsugawa, Koichiro
    Nakagawa, Shintaro
    Kanatani, Kazumitsu
    Nakayama, Takahiro
    IN VIVO, 2017, 31 (03): : 493 - 500
12345